: Moderna set to join S&P 500, stock rallies 8%


Moderna Inc., a biotechnology company catapulted to fame after it produced a highly effective COVID-19 vaccine, is set to join the S&P 500 index, a seal of approval that will put the stock in countless index-tracking and actively managed funds and retirement accounts.

Shares of Moderna

rallied 8% in the extended session Thursday after the announcement. The stock has gained 149% this year, compared with gains of 16% for the S&P 500

in the same period.

Moderna will replace Alexion Pharmaceuticals Inc.

at the opening on July 21, S&P Dow Jones Indices, the index manager, said in a statement.

Boston-area Moderna was a scrappy biotech startup relatively unknown before its successful COVID-19 vaccine, approved last year in the U.S. on an emergency basis for adults. The shot, like the one from Pfizer Inc.
uses messenger-RNA technology. Both vaccines have shown efficacy of more than 90%.

AstraZeneca Plc.
which also has developed a COVID-19 vaccine alongside Oxford University, is buying Alexion and the the $39 billion deal is expected to close soon. The companies announced the deal in December.

What’s Worth Streaming: Here’s what’s coming to Hulu in August 2021, and what’s leaving

Previous article

NewsWatch: Apple, Amazon, ARKK, and other big names indicate a market correction is coming, strategist says. Here’s why.

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News